ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,294.10
-0.42%
S&P ASX All Technology
3,845.90
-0.28%
Brent Oil
79.285
0.00%
US Dollar vs AUD
1.6276
0.00%
Bitcoin
94,591.48
-0.12%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Climb Bio Inc (CLYM) Share Price

Climb Bio Inc

Climb Bio Inc (CLYM)

NASDAQ
2.00
0.13
(6.95%)
Closed 12 January 8:00AM
Delayed by 15 minutes
2.00
-0.01
(-0.50%)
After Hours: 11:35AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.00
Bid
2.01
Offer
2.23
Volume
1,687,968
1.97 Day's Range 2.2669
1.73 52 Week Range 5.86
Market Cap
134.448M
Previous Close
1.87
Open
2.08
Last Trade
100
@
2
(formt)
Last Trade Time
Financial Volume
US$ 3,394,919
VWAP
2.0112
Average Volume (3m)
331,015
Shares Outstanding
67,223,760
Dividend Yield
-
PE Ratio
-9.78
Earnings Per Share (EPS)
-0.52
Revenue
-
Net Profit
-35.12M

About Climb Bio Inc

Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cel... Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Companys lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
climbbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Climb Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CLYM. The last closing price for Climb Bio was US$1.87. Over the last year, Climb Bio shares have traded in a share price range of US$ 1.73 to US$ 5.86.

Climb Bio currently has 67,223,760 shares in issue. The market capitalisation of Climb Bio is US$125.71 million. Climb Bio has a price to earnings ratio (PE ratio) of -9.78.

Ask ADVFN Intelligence (AI)

CLYM Latest News

More News

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody...

09 January 2025
GlobeNewswire Inc.

Climb Bio to be Added to the Nasdaq Biotechnology Index

WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq:...

19 December 2024
GlobeNewswire Inc.

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team...

13 November 2024
GlobeNewswire Inc.

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors...

11 November 2024
GlobeNewswire Inc.

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences...

31 October 2024
GlobeNewswire Inc.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development...

15 October 2024
GlobeNewswire Inc.

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take...

12 October 2024
GlobeNewswire Inc.

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases...

04 October 2024
GlobeNewswire Inc.

Climb Bio to Host Virtual Investor Event on October 15, 2024

WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of...

04 October 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.09-4.306220095692.092.361.872419172.18782505CS
4-0.9-31.03448275862.92.91.734560182.0596687CS
12-2.87-58.9322381934.875.11.733310152.963888CS
26-3.03-60.23856858855.035.861.733371043.35500845CS
52-3.03-60.23856858855.035.861.733371043.35500845CS
156-3.03-60.23856858855.035.861.733371043.35500845CS
260-3.03-60.23856858855.035.861.733371043.35500845CS

CLYM - Frequently Asked Questions (FAQ)

What is the current Climb Bio share price?
The current share price of Climb Bio is US$ 2.00
How many Climb Bio shares are in issue?
Climb Bio has 67,223,760 shares in issue
What is the market cap of Climb Bio?
The market capitalisation of Climb Bio is USD 125.71M
What is the 1 year trading range for Climb Bio share price?
Climb Bio has traded in the range of US$ 1.73 to US$ 5.86 during the past year
What is the PE ratio of Climb Bio?
The price to earnings ratio of Climb Bio is -9.78
What is the reporting currency for Climb Bio?
Climb Bio reports financial results in USD
What is the latest annual profit for Climb Bio?
The latest annual profit of Climb Bio is USD -35.12M
What is the registered address of Climb Bio?
The registered address for Climb Bio is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Climb Bio website address?
The website address for Climb Bio is climbbio.com
Which industry sector does Climb Bio operate in?
Climb Bio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.7M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.69M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.56M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.16B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.45M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

Discussion

View Full Feed
xxxx xxxx 2 minutes ago
u missed it
SHIBUSD
jour_trader jour_trader 2 minutes ago
I have plenty of experience with companies going through M&A as well, but not in the generic pharma market. How many generic pharma acquisitions have you been a part of? Industry means everything. I'd love nothing more than seeing a huge multiple. This is neither a tech stock or a company that has b
ELTP
Homebrew Homebrew 2 minutes ago
He needed victims to buy his shares. Same with the other long term pumpers.
...makes you wonder if he was in it from the start. ...
hap0206 hap0206 2 minutes ago
And we go to Indirect Subsidies to the oil/gas companies from the good ol americans -- per the environ fanatics -- such good folks
========
Indirect Subsidies

Last In, First Out Accounting (26 U.S. Code § 472. Active). The Last In, First Out accounting method (LIFO) allo
toohot toohot 2 minutes ago
This BIEL one from 3331:


WHICH CATALYST WILL BE FIRST?

1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/
BIEL QUBT
price_and_volume price_and_volume 3 minutes ago
Hello? Huggy been posting here ALSO since 2020...

In fact he was posting here PRIOR to TenKay, who started posting PRIOR to NoMoDo.

This is all neither here nor there of course, but why do you guys go off-topic to atack others and even THEN aren't particularly accurate
HMBL
StockItOut StockItOut 3 minutes ago
Duffy uses fake Nexboards all the time. Never uses real Nexboards as he and Xeriant have never produced Nexboard, evidenced by durever repeated fire testing that leads to durnever certification, nor actual production.
XERI
sodamnsane sodamnsane 3 minutes ago
It was likely a ploy to get investor information. Only thing you can do is pray they get what's coming to them or pay them a personal visit and show them what's coming. 
TSOI
12x 12x 4 minutes ago
Thank you for sharing your personal story about the AD trial.

The actual concern about high dropouts is poor drug tolerability, the bias risk, and the negative impact on the n. Regulators focus on those.

I completely agree. It's extremely challenging to bring a small-n
AVXL
janice shell janice shell 5 minutes ago
I think I would really have hated the Old West...
EmpressMonk25 EmpressMonk25 5 minutes ago
Is it only me, or can others also hear the wheels turning in TenKay and Huggies' heads?
HMBL
ubueltp ubueltp 5 minutes ago
That 8-12x is unrealisticly low for a growing company, in a growth market and a growing pipeline. To sell such a company, I would expect a minimum of 18x and as high as 25/26. I would expect this as I have significant experience in the selling and buying of companies. So, do your own DD and place yo
ELTP
joe_techi joe_techi 8 minutes ago
Great Harmonica. Always envied that capability
DKLN DKLN 9 minutes ago
Most likely nothing, That's why, after 6+ years, this stock sits at triple zeros with horrible volume and zippo revenue in the past 11 quarterly reports. Meanwhile, the kid generating revenue with his lemonade stand is working hard preparing some new flavored lemonade. BTW - The other two on this Bo
MCIC
Bubae Bubae 10 minutes ago
You were wrong to pump this stock and you are wrong to pump the other. The reasons I posted on the other board. You might try taking the conversation back over there. This isn't the place for it.
GRST
Involuntary-Recluse Involuntary-Recluse 11 minutes ago
https://investorshub.advfn.com/uimage/uploads/2025/1/11/fmybzToTheMoonTakingOffGIF.gif
CLHI
chrismiss_everyday chrismiss_everyday 12 minutes ago
Kudos to MayoMobile! 👏🧠🙌
AVXL
cottonmather cottonmather 13 minutes ago
Poplar Report. Ready or not Panama Canal , Greenland. 23 minutes https://youtu.be/beUO_EJKiAw?si=T2zIjs6TcOdnnbbe
Involuntary-Recluse Involuntary-Recluse 13 minutes ago
IMHO


FEAR= False Evidence Appearing Real ;-)

Better to REACT than to PREDICT 😂


Only Pinocchio 🤥 knows tomorrow for sure 😂 😂 😂


Carry on..
lowfloatmaster lowfloatmaster 13 minutes ago
Bro , come on.. 10.. u really think this company gunna get those contracts
I’m not buying it, and I own the stock
UMAV
lowfloatmaster lowfloatmaster 13 minutes ago
Bro , come on.. 10.. u really think this company gunna get those contracts
I’m not buying it, and I own the stock
UMAV
price_and_volume price_and_volume 13 minutes ago
What sort of DD is this?
NoMoDo, your involvement with the HUMBL ticker is clearly evident from your posting history well before the December surge. In contrast, TenKay only recently committed to the HUMBL ticker... a quick look indicates both gentlemen have been posting here pretty consisten
HMBL

Your Recent History

NASDAQ
CLYM
Climb Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads